Literature DB >> 21948355

Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome.

Leonard B Weinstock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21948355     DOI： 10.1007/s10620-011-1889-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  1 in total

1.  Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.

Authors:  Mark Pimentel; Walter Morales; Kathleen Chua; Gillian Barlow; Stacy Weitsman; Gene Kim; Meridythe M Amichai; Venkata Pokkunuri; Emily Rook; Ruchi Mathur; Zachary Marsh
Journal:  Dig Dis Sci       Date:  2011-05-11       Impact factor: 3.199
  1 in total
  2 in total

Review 1.  Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.

Authors:  Brian E Lacy
Journal:  Aliment Pharmacol Ther       Date:  2018-09-07       Impact factor: 8.171

2.  Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.

Authors:  Anthony Lembo; Satish S C Rao; Zeev Heimanson; Mark Pimentel
Journal:  Clin Transl Gastroenterol       Date:  2020-03       Impact factor: 4.396
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.